Molecular Response After 3 Months of 1st Line Imatinib Therapy Is Predictive for Treatment Failure and Disease Progression In Patients with Chronic Phase Chronic Myeloid Leukemia - a Follow-up Analysis of the German CML Study IV

被引：0

作者：

Hanfstein, Benjamin ^{[1
]}

Mueller, Martin C. ^{[1
]}

Erben, Philipp ^{[1
]}

Schnittger, Susanne ^{[2
]}

Saussele, Susanne ^{[1
]}

Leitner, Armin ^{[1
]}

Proetel, Ulrike ^{[1
]}

Ehninger, Gerhard ^{[3
]}

Hossfeld, Dieter K.

Kolb, Hans-Jochem ^{[4
,7
]}

Krause, Stefan W. ^{[5
]}

Nerl, Christoph ^{[6
]}

Pralle, Hans

Heim, Dominik ^{[8
]}

Baerlocher, Gabriela M.

Heimpel, Hermann ^{[9
]}

Hehlmann, Ruediger ^{[1
]}

Hochhaus, Andreas ^{[10
]}

机构：

[1] Univ Heidelberg, Med Fak Mannheim, Med Klin 3, D-6800 Mannheim, Germany

[2] MLL, Munich, Germany

[3] Univ Klinikum Carl Gustav Carus Dresden, Med Klin & Poliklin 1, Dresden, Germany

[4] Klinikum Univ Munchen Grosshadern, Med Klin & Poliklin 3, Munich, Germany

[5] Univ Klinikum Erlangen, Med Klin 5, Erlangen, Germany

[6] Krankenhaus Munchen Schwabing, Munich, Germany

[7] Univ Giessen, Giessen, Germany

[8] Univ Spital Basel, Dept Hematol, Basel, Switzerland

[9] Univ Ulm Klinikum, Innere Med Klin 3, Ulm, Germany

[10] Univ Klinikum Jena, Innere Med Klin 3, Jena, Germany

来源：

BLOOD | 2010年 / 116卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：162 / 163

页数：2

共 50 条

[31] Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study
Le Coutre, P. D.
Giles, F.
Hochhaus, A.
Apperley, J. F.
Ossenkoppele, G.
Haque, A.
Gallagher, N. J.
Baccarani, M.
Cortes, J.
Kantarjian, H.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[32] Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study
le Coutre, Philipp D.
Giles, Francis J.
Pinilla-Ibarz, Javier
Larson, Richard A.
Gattermann, Norbert
Ottmann, Oliver G.
Hochhaus, Andreas
Radich, Jerald P.
Saglio, Giuseppe
Hughes, Timothy P.
Martinelli, Giovanni
Kim, Dong-Wook
Branford, Susan
Mueller, Martin C.
Shou, Yaping
Novick, Steven
Fan, Xiaolin
Cortes, Jorge E.
Baccarani, Michele
Kantarjian, Hagop M.
BLOOD, 2011, 118 (21) : 1610 - 1610
[33] MOLECULAR RESPONSE KINETICS AND BCR-ABL REDUCTIONS IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) RECEIVING DASATINIB VS IMATINIB: DASISION 3-YEAR FOLLOW-UP
Hochhaus, A.
Boque, C.
Bradley Garelik, M.
Manos, G.
Steegmann, J. L.
HAEMATOLOGICA, 2012, 97 : 76 - 76
[34] IMPACT OF NON-ADHERENCE TO IMATINIB ON PROGRESSION-FREE SURVIVAL AS 1ST TREATMENT FOR CHRONIC MYELOID LEUKEMIA IN BRAZIL: TWO YEARS FOLLOW UP
Funke, V. A. M.
Moellmann-Coelho, A.
Asano, E.
Nita, M. E.
Donato, B. M.
Rahal, E.
VALUE IN HEALTH, 2011, 14 (03) : A168 - A169
[35] BELA trial update: Bosutinib (BOS) versus imatinib (IM) in patients (pts) with newly diagnosed chronic phase chronic myeloid leukemia (CP CML) after 30 months of follow-up.
Gambacorti-Passerini, Carlo
Lipton, Jeffrey Howard
Tee, Goh Yeow
Casado, Luis Felipe
Zaritskey, Andrey
le Coutre, Philipp D.
Duvillie, Ladan
Pavlov, Dmitri
Countouriotis, Athena Maria
Byrne, Jennifer
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[36] Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment
Hochhaus, Andreas
Druker, Brian
Sawyers, Charles
Guilhot, Francois
Schiffer, Charles A.
Cortes, Jorge
Niederwieser, Dietger W.
Gambacorti, Carlo
Stone, Richard M.
Goldman, John
Fischer, Thomas
O'Brien, Stephen G.
Reiffers, Jose J.
Mone, Manisha
Krahnke, Tillmann
Talpaz, Moshe
Kantarjian, Hagop M.
BLOOD, 2008, 111 (03) : 1039 - 1043
[37] INCIDENCE OF ABL KINASE DOMAIN MUTATIONS IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS WITH FAILURE OR SUBOPTIMAL RESPONSE TO FRONTLINE IMATINIB TREATMENT - AN ANALYSIS BY THE GIMEMA WORKING PARTY ON CML
Soverini, S.
Colarossi, S.
Gnani, A.
Castagnetti, F.
Abruzzese, E.
Orlandi, E.
Tiribelli, M.
Breccia, M.
Specchia, G.
Palandri, F.
Poerio, A.
Amabile, M.
Iacobucci, I.
Ciccarese, F.
Rosti, G.
Baccarani, M.
Martinelli, G.
HAEMATOLOGICA, 2008, 93 : S71 - S71
[38] Achievement and Maintenance Of Deeper Molecular Response By Switching To Nilotinib In Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With Residual Disease On Long-Term Imatinib: ENESTcmr 36-Month Follow-Up
Leber, Brian
Cervantes, Francisco
Spector, Nelson
Lipton, Jeffrey H.
Etienne, Gabriel
Pasquini, Ricardo
Clementino, Nelma Christina
Guerci-Bresler, Agnes
Forrest, Donna
Schwarer, Anthony P.
Acharya, Sandip
Collins, LaTonya
Szczudlo, Tomasz
Hughes, Timothy P.
BLOOD, 2013, 122 (21)
[39] Real-World Data from Long Term Follow-up in Chronic Myeloid Leukemia (CML) Patients (PTS) Treated with Imatinib. Predictive Factors for Achievement of Deep Molecular Responses and for Failure
Mela Osorio, Maria Jose
Amanda Giere, Isabel
Fernandez, Isolda
Pavlovsky, Miguel A.
Remaggi, Guillermina
Sackmann, Federico
Intile, Dante
Pavlovsky, Carolina
BLOOD, 2015, 126 (23)
[40] Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study
Naoto Takahashi
Tetsuzo Tauchi
Kunio Kitamura
Koichi Miyamura
Yoshio Saburi
Yoshihiro Hatta
Yasuhiko Miyata
Shinichi Kobayashi
Kensuke Usuki
Itaru Matsumura
Yosuke Minami
Noriko Usui
Tetsuya Fukuda
Satoru Takada
Maho Ishikawa
Katsumichi Fujimaki
Hiroshi Gomyo
Osamu Sasaki
Kohshi Ohishi
Takaaki Miyake
Kiyotoshi Imai
Hitoshi Suzushima
Hideki Mitsui
Kazuto Togitani
Toru Kiguchi
Yoshiko Atsuta
Shigeki Ohtake
Kazunori Ohnishi
Yukio Kobayashi
Hitoshi Kiyoi
Yasushi Miyazaki
Tomoki Naoe
International Journal of Hematology, 2018, 107 : 185 - 193

← 1 2 3 4 5 →